Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In clinical trials, patients are selected according to strict eligibility criteria (inclusion and exclusion criteria). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications. Indeed, patients of advanced age, with comorbidities or brain metastases, who are frequently encountered in clinical practice, are often excluded from clinical trials. Real-life data in oncology play a vital role in assessing the efficacy of therapies and therapeutic strategies, complementing data from controlled clinical trials. They make it possible to analyze a larger population and take into account multiple variables such as patient history, co-medications and comorbidities, but also to analyze efficacy and toxicity data in populations not represented in clinical trials. The establishment of a prospective cohort including various stages and histologies will make it possible to set up a platform of available data, including a maximum of data linked to the patient, his tumor and his treatments, collected longitudinally until the patient's death (or the end of the study). In parallel with this cohort, the project aims to set up a longitudinal plasmatheque (from diagnosis to death, or at the end of the study), as well as a tumorotheque (samples systematically stored as part of care by the CHU tumorotheque, and for which patient consent allows their use in research depending on the material available) for patients with available tumor samples. This will enable the construction of ancillary projects to validate research hypotheses, for example concerning the identification of mechanisms of resistance to therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosły pacjent ze świeżo rozpoznanym rakiem płuca (typ NSCLC lub CPC)
- •Pacjent leczony w Szpitalu Uniwersyteckim w Nantes
- •Objęty ubezpieczeniem społecznym lub równoważnym
- •Leczony chemioterapią, immunoterapią, terapią celowaną lub biorący udział w innym badaniu klinicznym
- •Wyraził pisemną zgodę na uczestnictwo w badaniu
- •Osoba zdrowa bez historii nowotworów i chorób zakaźnych może być również uczestnikiem
✗ Disqualifies
- •Wcześniejsze leczenie raka płuca
- •Brak pisemnej zgodny na uczestnictwo w badaniu
- •Historia innych nowotworów (poza płucami) w ciągu ostatnich 2 lat
- •Uczestnictwo w innym badaniu z zaślepionym leczeniem
- •Pacjent pod opieką prawną lub pobierający pomoc medyczną państwa
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
CHU d'Angers
Angers, France
CHU Nantes
Nantes, France
CHU Rennes
Rennes, France
CHU Tours
Tours, France
Trial contact
Elvire PONS-TOSTIVINT, MD PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.